Lumena Pharmaceuticals Gets $23M

San Diego-based Lumena Pharmaceuticals announce today that it has raised $23M in a Series A funding round, to go towards developing oral therapeutics for rare liver diseases. The funding came from Pappas Ventures, RiverVest Venture Partners and Alta Partners. According to Lumena, the new funds will go towards clinical development of its lead product candidate, which is aimed at treating cholestatic liver disease in pediatric and adult patients. Lumena said it has added David R. Savello of Pappas Ventures, John McKearn of RiverVest, and Robert Alexander of ZS Pharma to its board as part of the funding. More information »